The evolution of haematological and biochemical indices in HIV patients during a six-month treatment period

African Health Sciences

Volumn 12, Issue 1, 2012, Pages 1-6

  Mgogwe, J ^a   Semvua, H ^c   Msangi, R ^e   Mataro, C ^b,d   Kajeguka, D ^b,c   Chilongola, J ^b,c  

^a Kibongoto National TB Hospital   (Tanzania)

^b Faculty of Medicine Kilimanjaro Christian Medical College   (Tanzania)

^c KILIMANJARO CLINICAL RESEARCH INSTITUTE   (Tanzania)

^d KILIMANJARO CHRISTIAN MEDICAL CENTRE   (Tanzania)

^e Bumbuli Hospital   (Tanzania)

Author keywords

Anemia; ARV; HIV

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CREATININE; HEMOGLOBIN; STAVUDINE; ZIDOVUDINE; ANTIRETROVIRUS AGENT; BIOLOGICAL MARKER;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD CHEMISTRY; CD4 LYMPHOCYTE COUNT; CHRONIC DRUG ADMINISTRATION; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; IRON DEFICIENCY ANEMIA; LEUKOCYTE DIFFERENTIAL COUNT; LEUKOPENIA; LIVER INJURY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MONOCYTE; OUTCOME ASSESSMENT; PANCREAS INJURY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; BLOOD; BLOOD EXAMINATION; CD4+ T LYMPHOCYTE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; LYMPHOCYTE COUNT; METABOLISM; MIDDLE AGED; SOCIOECONOMICS; TANZANIA; TIME; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ADOLESCENT; ADULT; ALANINE TRANSAMINASE; AMYLASES; ANTI-RETROVIRAL AGENTS; BIOLOGICAL MARKERS; CD4-POSITIVE T-LYMPHOCYTES; CHOLESTEROL; CREATININE; FEMALE; HEMATOLOGIC TESTS; HIV INFECTIONS; HIV-1; HUMANS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; SOCIOECONOMIC FACTORS; TANZANIA; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84859833023     PISSN: 16806905     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997 Sep 11; 337 (11):725-733.
2. Rosenberg ES, Altfeld M, Poon SH, Phillips MN, Wilkes BM, Eldridge RL, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000 Sep 28;407(6803):523-526.
3. Idigbe EO, Adewole TA, Eisen G, Kanki P, Odunukwe NN, Onwujekwe DI, et al. Management of HIV-1 infection with a combination of nevirapine, stavudine, and lamivudine: a preliminary report on the Nigerian antiretroviral program. J Acquir Immune Defic Syndr 2005 Sep 1;40(1):65-69.
4. WHO/UNAIDS, Epidemiology fact sheet on HIV/AIDS & sexually transmitted infection(2004)
5. Jacobson MA, Peiperl L, Volberding PA, Porteous D, Toy PT, Feigal D. Red cell transfusion therapy for anaemia in patients with AIDS and ARC: incidence, associated factors, and outcome. Transfusion 1990 Feb;30(2):133-137.
6. Scadden DT, Zeira M, Woon A, Wang Z, Schieve L, Ikeuchi K, et al. Human immunodeficiency virus infection of human bone marrow stromal fibroblasts. Blood 1990 Jul 15;76(2):317-322.
7. Pamela SB, David CR. Prevalence and outcome of anaemia in individual with Human immunideficiency Virus: a systematic review of literature. The American journal of Medicine 2004; 116(6), 27-43
8. Kredo T, Van der Walt JS, Siegfried N, Cohen K. Therapeutic drug monitoring of antiretrovirals for people with HIV. Cochrane Database Syst Rev 2009;(3):CD007268.
9. Pryce C, Pierre RB, Steel-Duncan J, Evans- Gilbert T, Palmer P, Moore J, et al. Safety of antiretroviral drug therapy in Jamaican children with HIV/AIDS. West Indian Med J 2008 Jun;57(3):238-245.
10. Coyle TE. Haematologic complications of human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Med Clin North Am 1997 Mar;81(2):449-470.
11. Minzi OM, Irunde H, Moshiro C. HIV patients presenting common adverse drug events caused by highly active antiretroviral therapy in Tanzania. Tanzan J Health Res 2009 Jan;11(1):5-10.
12. Tymchuk CN, Currier JS. The safety of antiretroviral drugs. Expert Opin Drug Saf 2008 Jan;7(1):1-4.
13. Miyamoto M, Pessoa SD, Ono E, Machado DM, Salomao R, Succi RC, et al. Low CD4+ T-cell levels and B-cell apoptosis in vertically HIV-exposed noninfected children and adolescents. J Trop Pediatr 2010 Dec;56 (6):427-432.
14. Schacker TW, Bosch RJ, Bennett K, Pollard R, Robbins GK, Collier AC, et al. Measurement of naive CD4 cells reliably predicts potential for immune reconstitution in HIV. J Acquir Immune Defic Syndr 2010 May 1;54 (1):59-62.
15. Gitura B, Joshi MD, Lule GN, Anzala O. Total lymphocyte count as a surrogate marker for CD4+ t cell count in initiating antiretroviral therapy at Kenyatta National Hospital, Nairobi. East Afr Med J 2007 Oct; 84(10):466-472.
16. Shah ZA, Rasool R, Siddiqi MA. Effect of highly active anti-retroviral therapy on CD3+/CD4+/CD8+ T lymphocyte counts in HIV seropositive Kashmiri patients: a follow up study. Indian J Pathol Microbiol 2007 Jul; 50(3):648-651.
17. dje-Toure CA, Cheingsong R, Garcia-Lerma JG, Eholie S, Borget MY, Bouchez JM, et al. Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Cote d'Ivoire. AIDS 2003 Jul; 17 Suppl 3:S49-S54.
18. Covas DT, Boturao NE, Zago MA. The frequency of blood-born viral infections in a population of multitransfused Brazilian patients. Rev Inst Med Trop Sao Paulo 1993 May; 35 (3):271-273.
19. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV- 1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002 Jul 13; 360(9327):119-129.
20. Kofu K, Gresham Dame GM, Peter MT. Rapid Spread of HIV infection in Abjan, Ivory Coast. Europe J, micro. Infect Dis. 2007; 20: 11-27.